ClinicalTrials.gg
Enrolling by invitationNCT00762866PGPPUpdated Jan 27, 2026

Psychiatric Genotype/Phenotype Project Repository

An observational study in Depressive Disorder, Major, Bipolar Disorder and Psychotic Disorders, sponsored by Vanderbilt University. Enrolling by invitation at 1 site in United States. Open to participants aged 16 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Vanderbilt University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 216 open to participants now, 258 under way, 26 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
10th of 171
2,000 · median 100
Started
2008
with 61 others
Observational
171 of 1,500
22 open now
Primary completion
2027-12
later than 139 of 257 live
Registered
311th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 10th largest by planned enrollment of the 171 observational ones that give a count, is one of 62 that started in 2008, is one of 171 observational ones, reaches primary completion later than 139 of the 257 other live ones, and was the 311th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

216 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

211 more — sign in →

All 216 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The purpose of this project is to obtain DNA, brain imaging data, other biological samples (e.g., urine, serum), and a comprehensive clinical assessment on patients with schizophrenia and other psychotic disorders, bipolar disorder, major depression, and normal volunteer controls. Understanding the physical and genetic factors related to these disorders will help us make progress in fitting treatments to an individual's needs. Participants will take part in a detailed clinical assessment, two blood draws, and an MRI scan over two visits. Participants will also be asked to provide urine and saliva samples.

Read the detailed description

The links between psychiatric symptoms and underlying biological processes remain unclear at this time. Unipolar Major Depressive Disorder, Bipolar Disorder, and Schizophrenia are associated with major disruptions in functioning and quality of life. Understanding the causal physiological and genetic factors involved in each of these disorders would allow us to make great strides in tailoring treatment to the individual's needs. Because the etiology of these disorders are likely multifactorial in nature, a study examining a wide range of variables might best allow us to examine the interactions between different factors and to get a better sense of how genes and the brain interact to produce psychiatric disorder.

03

Conditions studied

  • Depressive Disorder, Major
  • Bipolar Disorder
  • Psychotic Disorders

Keywords

  • Major Depressive Disorder
  • Depression
  • Bipolar I Disorder
  • Bipolar II Disorder
  • Bipolar Disorder NOS
  • Psychotic Disorder
  • Schizophrenia
  • Schizoaffective Disorder
04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Outpatient Mental Health Clinic, Inpatient Psychiatric Hospital, Research Volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between the ages of 16 and 65
  2. Able and willing to provide
  3. Able to read and speak English sufficiently to provide consent and answer questions
  4. Diagnosis of one of the following:

    • Unipolar Major Depressive Disorder of any subtype
    • Bipolar I, Bipolar II Disorder, or Bipolar Disorder NOS
    • Axis I Psychotic Disorder, which can include the diagnoses of Schizophrenia, Schizoaffective Disorder, Major Depression or Mania with Psychotic Features, Schizophreniform Disorder, Brief Psychotic Episode, or Psychotic Disorder NOS
    • Normal volunteer controls, individuals with no personal history of any Axis I disorder.

Exclusion criteria

Exclusion Criteria:

  1. Reported pregnancy or breastfeeding
  2. Dementia or delirium
  3. Any medical condition that would interfere with participation in the study. This would include, but not be limited to:

    • uncontrolled diabetes, hypothyroidism, Cushing's disease, or other significant endocrine condition (treated endocrine condition is allowed)
    • demyelinating disease
    • infection
    • active hepatitis
    • CNS infection
    • and unstable cardiovascular disease
    • any cancer involving the CNS (including disease)
  4. Exclusion criteria for normal control subjects include any history of mental illness or psychotropic drug abuse.
  5. Participants will be excluded from the imaging portion of the study if they have any condition deemed to interfere with PET or MRI scanning, such as but not restricted to extreme obesity, metal fragments in eyes, metal implants in the head, or cochlear implant. These participants may still take part in the portion of the study involving the clinical assessment and providing biological samples.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000 participants (estimated)
Target follow-up
2 Weeks
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • MDD

    Unipolar Major Depressive Disorder, any subtype

  • Bipolar

    Bipolar I or II Disorder or Bipolar Disorder NOS

  • Psychosis

    Psychotic Disorder including Schizophrenia, Schizoaffective, Schizophreniform, Brief Psychotic Disorder, and Psychotic Disorder NOS

06

What researchers measure

Primary outcomes

  1. Brain volume

    Observational neuromaging study

    Time frame: 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2008 (actual). Primary completion is estimated for Dec 2027, 231 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2008
First posted
Sep 30, 2008
StartActual
Sep 2008
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00762866
Responsible party
Stephan Heckers (Chair of the Department of Psychiatry, Vanderbilt University) — Principal investigator
First posted
Sep 30, 2008
Start date
Sep 2008
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 27, 2026

Study contacts

Stephan Heckers, M.D.
principal investigator · Vanderbilt University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion